These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28404893)

  • 1. A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer.
    Chen Y; Shao Z; Chen W; Xie H; Wu Z; Qin G; Zhao N
    Oncotarget; 2017 May; 8(18):29925-29934. PubMed ID: 28404893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer.
    Boeck S; Haas M; Laubender RP; Kullmann F; Klose C; Bruns CJ; Wilkowski R; Stieber P; Holdenrieder S; Buchner H; Mansmann U; Heinemann V
    Clin Cancer Res; 2010 Feb; 16(3):986-94. PubMed ID: 20103662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
    An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
    Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients.
    Song JY; Chen MQ; Guo JH; Lian SF; Xu BH
    Medicine (Baltimore); 2018 Jan; 97(4):e9707. PubMed ID: 29369199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.
    Haas M; Laubender RP; Stieber P; Holdenrieder S; Bruns CJ; Wilkowski R; Mansmann U; Heinemann V; Boeck S
    Tumour Biol; 2010 Aug; 31(4):351-7. PubMed ID: 20480409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of SUVmax and serum carbohydrate antigen 19-9 in pancreatic cancer.
    Zhao JG; Hu Y; Liao Q; Niu ZY; Zhao YP
    World J Gastroenterol; 2014 May; 20(19):5875-80. PubMed ID: 24914348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
    Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
    Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer.
    Usón Junior PLS; Callegaro-Filho D; Bugano DDG; Moura F; Maluf FC
    J Gastrointest Cancer; 2018 Dec; 49(4):481-486. PubMed ID: 28924968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Cancer.
    Sakamoto T; Saito H; Uchinaka EI; Morimoto M; Amisaki M; Tokuyasu N; Honjo S; Ashida K; Fujiwara Y
    Anticancer Res; 2018 Sep; 38(9):5497-5503. PubMed ID: 30194208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.
    Bauer TM; El-Rayes BF; Li X; Hammad N; Philip PA; Shields AF; Zalupski MM; Bekaii-Saab T
    Cancer; 2013 Jan; 119(2):285-92. PubMed ID: 22786786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.
    Reni M; Peretti U; Zanon S; Macchini M; Balzano G; Mazza E; Tamburrino D; Orsi G; Arcidiacono PG; Falconi M; Gianni L
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):641-650. PubMed ID: 32157412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of the neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 in estimating survival in patients with metastatic pancreatic cancer.
    Cetin S; Dede I
    J Cancer Res Ther; 2020; 16(4):909-916. PubMed ID: 32930139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy.
    Hammad N; Heilbrun LK; Philip PA; Shields AF; Zalupski MM; Venkatramanamoorthy R; El-Rayes BF
    Asia Pac J Clin Oncol; 2010 Jun; 6(2):98-105. PubMed ID: 20565421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma microRNA192 in combination with serum CA19-9 as non-invasive prognostic biomarker in periampullary carcinoma.
    Murali Manohar K; Sasikala M; Kvsrr Y; Sunil V; Talukdar R; Murthy H; Ramji C; Rao GV; Pradeep R; Reddy DN
    Tumour Biol; 2017 Mar; 39(3):1010428317695018. PubMed ID: 28351309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype.
    Luo G; Liu C; Guo M; Long J; Liu Z; Xiao Z; Jin K; Cheng H; Lu Y; Ni Q; Yu X
    Cancer Lett; 2017 Jan; 385():46-50. PubMed ID: 27840089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer.
    Saad ED; Reis PT; Borghesi G; Machado MC; Simon SD; Tabacof J; Gansl RC
    Rev Assoc Med Bras (1992); 2010; 56(1):22-6. PubMed ID: 20339781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic and predictive value of serum CA19.9 in pancreatic cancer.
    Humphris JL; Chang DK; Johns AL; Scarlett CJ; Pajic M; Jones MD; Colvin EK; Nagrial A; Chin VT; Chantrill LA; Samra JS; Gill AJ; Kench JG; Merrett ND; Das A; Musgrove EA; Sutherland RL; Biankin AV;
    Ann Oncol; 2012 Jul; 23(7):1713-22. PubMed ID: 22241899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer.
    Terao T; Kumagi T; Hyodo I; Yokota T; Azemoto N; Miyata H; Kuroda T; Ohno Y; Tanaka Y; Shibata N; Imamura Y; Kanemitsu K; Miyake T; Koizumi M; Hiasa Y;
    Medicine (Baltimore); 2021 Oct; 100(43):e27591. PubMed ID: 34713835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
    Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
    Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CA19-9 for detecting recurrence of pancreatic cancer.
    Azizian A; Rühlmann F; Krause T; Bernhardt M; Jo P; König A; Kleiß M; Leha A; Ghadimi M; Gaedcke J
    Sci Rep; 2020 Jan; 10(1):1332. PubMed ID: 31992753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.